Moody Aldrich Partners LLC Has $1.03 Million Holdings in BioXcel Therapeutics Inc (NASDAQ:BTAI)

Moody Aldrich Partners LLC lessened its stake in BioXcel Therapeutics Inc (NASDAQ:BTAI) by 75.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,377 shares of the company’s stock after selling 60,265 shares during the quarter. Moody Aldrich Partners LLC’s holdings in BioXcel Therapeutics were worth $1,027,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BTAI. Advisor Group Holdings Inc. acquired a new stake in shares of BioXcel Therapeutics in the 1st quarter valued at approximately $39,000. Victory Capital Management Inc. lifted its holdings in BioXcel Therapeutics by 39.6% during the 1st quarter. Victory Capital Management Inc. now owns 1,874 shares of the company’s stock valued at $42,000 after purchasing an additional 532 shares during the last quarter. Citigroup Inc. lifted its holdings in BioXcel Therapeutics by 49.1% during the 1st quarter. Citigroup Inc. now owns 2,074 shares of the company’s stock valued at $46,000 after purchasing an additional 683 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in BioXcel Therapeutics by 134.5% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,089 shares of the company’s stock valued at $47,000 after purchasing an additional 1,198 shares during the last quarter. Finally, US Bancorp DE acquired a new stake in BioXcel Therapeutics during the 1st quarter valued at $68,000. 29.71% of the stock is owned by institutional investors.

BTAI stock traded down $3.11 during trading hours on Friday, hitting $45.36. 1,300,600 shares of the stock were exchanged, compared to its average volume of 794,181. The company has a quick ratio of 6.82, a current ratio of 6.82 and a debt-to-equity ratio of 0.01. The company has a 50-day simple moving average of $53.66 and a two-hundred day simple moving average of $35.81. BioXcel Therapeutics Inc has a 12 month low of $3.76 and a 12 month high of $71.50.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.21). On average, equities analysts anticipate that BioXcel Therapeutics Inc will post -2.96 earnings per share for the current year.

Several brokerages have issued reports on BTAI. Guggenheim began coverage on BioXcel Therapeutics in a report on Thursday, June 4th. They set a “buy” rating and a $101.00 price target for the company. Canaccord Genuity raised their price target on BioXcel Therapeutics from $71.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. BidaskClub raised BioXcel Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 25th. BMO Capital Markets raised their price target on BioXcel Therapeutics from $64.00 to $104.00 and gave the company a “positive” rating in a report on Monday, July 20th. Finally, Bank of America increased their price objective on BioXcel Therapeutics from $53.00 to $63.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. BioXcel Therapeutics presently has an average rating of “Buy” and an average target price of $102.00.

BioXcel Therapeutics Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Featured Article: Special Dividends

Want to see what other hedge funds are holding BTAI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioXcel Therapeutics Inc (NASDAQ:BTAI).

Institutional Ownership by Quarter for BioXcel Therapeutics (NASDAQ:BTAI)

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News